Microsoft word - dispelling the myths bibliography.doc

Clinicals – Dispelling the Myths Index 1 NICE - Long-acting reversible contraception. Baxter N, Hudson H, Rogerson L, Duffy S. 2 Hysteroscopic sterilisation: a study of women’s attitudes to a novel procedure. Faculty of Family Planning and Reproductive Heath Care Guidance (April 2004). 3 The Levonorgestrel-releasing Intrauterine System (LNG-IUS) in contraception and reproductive health. The Journal of Family Planning and Reproductive Health Care 2004; Vol 30, No 2, p.99-108. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I,Koskenvuo M. 4 Length of use and symptoms associated with premature removal of the Levonorgestrel Intrauterine System: A nationwide study of 17,360 users. BJOG 2000; Vol. 107, p.335-339. 5 Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception, January 1994; 49, p.56-72. 6 Clinical performance of the Levonorgestrel Intrauterine System in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. The Journal of Family Planning and Reproductive Health Care 2002; 28(2), p.73-77. 7 Day case sterilization with the Filshie Clip in Nottingham. 10-year follow-up study: the first 200 cases. ISGE 7th Annual Meeting, March 1998. Hulka JF, Noble AD, Letchworth AT, Lieberman B, Owen, E, Gomel V, Taft RC, Haney AF, Wheeless CR, Imrie Reversibility of clip sterilizations. Lancet 1982, Oct 23; 2(8304): 927 Peterson HB, Xia Z, Hughes JM, Wilcox LS, Ratliff Tylor L, Trussell J. 9 The risk of pregnancy after tubal sterilization: Findings for the US Collaborative Review of Sterilization. American Journal Obstetrics & Gynaecology, April 1996, 174:1161-1170 (CREST Study). 10 Update on female sterilisation: report from an international symposium at the 6th International Scientific Meeting of the Royal College of Obstetricians and Gynaecologists (to be published). 11 Female sterilisations with Filshie Clips: what is the risk failure? A retrospective survey of 30,000 applications. The Journal of Family Planning & Reproductive Health Care 2002; 28(1):34-5. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Ratliff Tylor L, Trussell J. 12 The risk of Ectopic Pregnancy after Tubal Sterilization: for The US Collaborative Review of Sterilization Working Group. The New England Journal of Medicine, 13 March 1997, Vol. 336(11):762-767. Nwagbara PN, Stibbe HM, Browning AJ, Tonks AM. 13 Reversal of female sterilisation experience in a district general hospital. Journal of Obstetrics and Gynaecology (1997), Vol. 17, No. 3, p.293-297. Duffy S, Marsh F, Rogerson L, Hudson H, Cooper K, Jack S, Hunter D, Philips G. 14 Female sterilisation: a cohort controlled comparative study of ESSURE versus laparoscopic sterilisation. BJOG, Nov 2005, Vol. 112, p.1522-1528. 15 Royal College of Obstetricians and Gynaecologists. Evidence-based Clinical Guideline Number 4, Male and Female Sterilisation. January 2004. Presentation made by Prof. Theodore King, 26 Feb 1996. 17 Implementing the NICE clinical guideline on long-acting reversible contraception. Clinical Guideline No. 30, December 2005. 18 Long term experience with the Filshie Clip. Gynaecology Forum, Vol. 7, Issue 3, 2002. 19 Conceptus / Essure Patient Information Brochure Cooper JM, Carignan CS, Cher D, Kerin JF. 20 Microinsert non-incisional hysteroscopic sterilization. Obstetrics & Gynaecology 2003; 102(1):59-67. 21 New developments Advances in hysterorscopic sterilisation. The Obstetrician & Gynaecologist. 2006; 8:103-106.

Source: http://www.nikomed.co.uk/docs/Dispelling%20the%20Myths%20Bibliography.pdf

Q7390_lignol_2_0_w_v_s.1_8.tp

Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel: 01939 211200 LIGNOL ® 2.0% W/V SOLUTION FOR INJECTION Overdose: Local anaesthetics may have systemicadverse effects as a result of the raised plasma Presentation Contains: Active substances: concentrations which occur when the rate of a

Microsoft powerpoint - benigninafplio0309.ppt

Kidney proteomic analysis in patients with diabetic nephropathy Ariela Benigni Mario Negri Institute for Pharmacological Research Bergamo, Italy TYPE 2 DIABETES MELLITUS IS A PUBLIC HEALTH CONCERN People with diabetes: (2004-2030) * In million subjects Developed Developing THE FACT 40 % of type 1 and of type 2 diabetics are at risk of overt nephropathy

© 2008-2018 Medical News